Cancer
Commented by Mario Hose on August 2nd, 2022 | 10:57 CEST
Defence Therapeutics VP Research + Development Dr. Moutih Rafei on the next generation oncology-targeting therapies
The publicly traded biotechnology company called Defence Therapeutics is developing new vaccines and ADC products on its own proprietary platform. The Accum technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency.
Read